Immunovant Inc. (IMVT) reported its fourth-quarter and full-year fiscal 2026 financial results and provided corporate updates, including new data from its lead candidate IMVT-1402.
For the quarter ended March 31, 2026, the company recorded a net loss of $147.9 million, or $0.73 per share, compared with a net loss of $106.4 million, or $0.64 per share, in the same quarter of 2025.
For the full fiscal year 2026, net loss widened to $505.6 million, or $2.77 per share, from $413.8 million, or $2.73 per share, in fiscal 2025.
Research and development expenses rose to $142.3 million in the quarter, up from $93.7 million a year earlier, driven by IMVT-1402 clinical trial activity and costs related to discontinuation of batoclimab.
General and administrative expenses decreased to $17.3 million from $20.2 million a year earlier.
Cash and cash equivalents stood at $902.1 million as of March 31, 2026, providing runway through the potential launch of IMVT-1402 in Graves' disease.
Clinical Updates
The company's pipeline includes IMVT-1402, which is advancing across multiple indications. The company confirmed that all other IMVT-1402 development timelines remain on track, including potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD).
-IMVT-1402 in Graves' disease: Phase 3 program ongoing, with topline data expected in 2027.
- IMVT-1402 in rheumatoid arthritis (D2T RA) Phase 3 trial ongoing; Immunovant announced preliminary Week 16 results from its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA), showing ACR20, ACR50, ACR70 response rates 72.7%, 54.5%, and 35.8% respectively.
- IMVT-1402 in Sjögren's disease Phase 3 program ongoing.
- IMVT-1402 in myasthenia gravis Phase 3 program ongoing, topline data expected in 2027.
- IMVT-1402 in chronic inflammatory demyelinating polyneuropathy: Phase 3 program ongoing. Topline data from the fully enrolled proof-of-concept trial are expected in 2H 2026.
Following topline results from two Phase 3 studies of batoclimab in thyroid eye disease (TED) that did not meet primary endpoints, Immunovant discontinued batoclimab development to focus fully on IMVT-1402.
IMVT has traded between $13.79 and $30.16 over the past year. The stock closed Tuesday's trading at $26.29, down 0.90%. In pre-market trading the stock is at $33.77, up 26.85%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.